A new trading day began on Friday, with Relay Therapeutics Inc (NASDAQ: RLAY) stock price up 0.31% from the previous day of trading, before settling in for the closing price of $3.19. RLAY’s price has ranged from $1.77 to $10.72 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 307.65% over the last five years. Meanwhile, its annual earnings per share averaged 12.43%. With a float of $127.71 million, this company’s outstanding shares have now reached $167.76 million.
The firm has a total of 261 workers. Let’s measure their productivity. In terms of profitability, gross margin is 72.39%, operating margin of -3854.04%, and the pretax margin is -3374.72%.
Relay Therapeutics Inc (RLAY) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Relay Therapeutics Inc is 24.67%, while institutional ownership is 80.06%. The most recent insider transaction that took place on Apr 23 ’25, was worth 182,423. In this transaction President and CEO of this company sold 61,422 shares at a rate of $2.97, taking the stock ownership to the 821,667 shares. Before that another transaction happened on Mar 27 ’25, when Company’s President, R&D sold 986 for $2.84, making the entire transaction worth $2,800. This insider now owns 615,052 shares in total.
Relay Therapeutics Inc (RLAY) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.09% during the next five years compared to -23.05% drop over the previous five years of trading.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Here are Relay Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 15.95. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 54.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.40, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -2.15 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
Analysing the last 5-days average volume posted by the [Relay Therapeutics Inc, RLAY], we can find that recorded value of 2.01 million was lower than the volume posted last year of 2.47 million. As of the previous 9 days, the stock’s Stochastic %D was 96.00%. Additionally, its Average True Range was 0.26.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 33.89%, which indicates a significant decrease from 98.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.60% in the past 14 days, which was lower than the 87.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.12, while its 200-day Moving Average is $5.34. Now, the first resistance to watch is $3.27. This is followed by the second major resistance level at $3.33. The third major resistance level sits at $3.45. If the price goes on to break the first support level at $3.08, it is likely to go to the next support level at $2.96. Now, if the price goes above the second support level, the third support stands at $2.90.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
With a market capitalization of 542.47 million, the company has a total of 169,522K Shares Outstanding. Currently, annual sales are 10,010 K while annual income is -337,710 K. The company’s previous quarter sales were 0 K while its latest quarter income was -76,000 K.
